News from EHA. Linfomi. Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma
|
|
- Lynne Dean
- 5 years ago
- Views:
Transcription
1 News from EHA Linfomi Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma
2 Outline HD advanced disease first line therapy : intensity of chemotherapy and PET guided radiotherapy New drugs relapsed/refractory HD : Brentuximab Vedotin DLBCL first line therapy : R-CHOP 21 vs R-CHOP 14, role of consolidation radiotherapy New drugs relapsed/refractory ALCL : Crizotinib
3 Comparing intensity of chemotherapy followed PET-Guided radiotherapy in patients with adavanced stage Hodgkin lymphoma: final results of the GHSG HD15 trial A.M. Engert Engert EHA 2012 abs 1108 oral session
4
5 GHSG 15 trial: results PTS= BEACOPP esc (%) 6 BEACOPP esc (%) 8 BEACOPP 14 (%) CR yrs FFTF yrs OS Hematol. toxici?es Sec. AML/MDS (29) 19 (2,7%) 2(0.3%) 8((1.1%) More effective and less toxic
6 (n=832) Engert EHA 2012 abs 1108 oral session
7
8 GHSG 15 trial: conclusions 6 BEACOPP escaleted followed PET- guided IFRT are more effeclve and less toxic than 8 BEACOPP escaleted In the HD- 15 only 11% of all palents received IFRT as compared to 71% in the prior HD- 9 study PET performed auer chemotherapy can guide the need of addilonal IFRT and reduces the number of pts requiring RT Engert EHA 2012 abs 1108 oral session
9 Long term follow up results of an ongoing PIVOTAL study of Brentuximab vedotin in patients with relapsed or refractory Hodgkin Lymphoma (HL) S.Smith Smith et al EHA 2012 abs 1109 oral session
10
11
12 Smith et al EHA 2012 abs 1109 oral session
13 Smith et al EHA 2012 abs 1109 oral session
14 Smith et al EHA 2012 abs 1109 oral session
15 Smith et al EHA 2012 abs 1109 oral session
16
17
18
19 Younes et al EHA 2012 educational
20 Younes et al EHA 2012 educational
21
22 Younes et al EHA 2012 educational
23 Younes et al EHA 2012 educational
24 Younes et al EHA 2012 educational
25 Panobinostat
26 D S H N H L RICOVER-60-no-RX Role of Radiotherapy for elderly DLBCL Patients in the Rituximab Era: Final Results of the RICOVER-60-no-RX Study of the German High Grade Non-Hodgkin s Lymphoma Study Group (DSHNHL) Gerhard Held, Niels Murawski, Marita Ziepert, Viola Pöschel, Carsten Zwick, Marcel Reiser, Sibylla Wilhelm, Tobias Gaska, Michael Heike, Joerg Schubert, Norbert Schmitz, Markus Loeffler, Christian Ruebe, and Michael Pfreundschuh for the DSHNHL Held et al EHA 2012 abs 1114 oral session
27 Radiotherapy in the Rituximab Era Objective: To assess the role of additional radiotherapy to bulky disease in elderly patients with DLBCL in the setting of 6xR- CHOP R
28 Radiotherapy in the Rituximab Era RICOVER-60 6 x CHOP Gy (Bulk, E) Response Cheson, JCO, 1999 CD20 + DLBCL Std. I-IV Jahre Random 2x2 Factorial Design 8 x CHOP Gy (Bulk, E) 6 x CHOP Gy (Bulk, E) + 8 x Rituximab RICOVER-60-no-RX 6 x CHOP Gy (Bulk, E) + 8 x Rituximab RICOVER-60-no-RX: 8 x CHOP Gy (Bulk, E) + 8 x Rituximab - 3rd Amendment - Recruitment 08/ / Number of Patients Median Observation 39 Months
29 Radiotherapy in the Rituximab Era D e m o g r a p h y p= p= p= p= p=0.024 RICOVER-60 RICOVER-60- no-rx Age (years) Stage III/IV IPI=3-5 Extranodal disease Bulky Disease
30 Bulky Disease: Tx according Protocol EFS PFS OS 80% [95%CI: 71-89] 88% [95%-CI: 80-95] 90% [95%-CI: 84-97] 54% [95%-CI: 38-71] 62% [95%-CI: 46-78] 65% [95%-CI: 49-81] p=0.001 p<0.001 p=0.001 months RICOVER-60 RICOVER-60-no-RX (n=78) (n=35)
31 Bulky Disease: Tx according Protocol PFS: Multivariate analysis adjusted for strata Factor Relative risk p-value 95% CI Rx vs. no Rx (1.8; 10.6) LDH > UNV (0.2; 1.7) ECOG > (0.5; 4.9) Extranodal involvement > (0.3; 2.4) Stage III/ IV (0.5; 3.4) Age > 70 years (0.7; 3.9)
32 Bulky Disease: CR/CRu after R-CHOP-14 EFS PFS OS p=0.439 p=0.430 p=0.839 months RICOVER-60 RICOVER-60-no-RX (n=33) (n=20)
33 Bulky Disease: PR after R-CHOP-14 EFS PFS OS p<0.001 p=0.025 p=0.019 months RICOVER-60 RICOVER-60-no-RX (n=84) (n=27)
34 Radiotherapy in the Rituximab Era Conclusions: Rx of bulk appears not to be beneficial for patients in CR/CRu after 6xR- CHOP-14 Rx to bulk appears to be beneficial for patients in PR after 6xR-CHOP-14 Limitations: No randomized trial Imbalanced demographics Response evaluation according to Cheson 1999 Role of PET remains unclear
35 Radiotherapy in the Rituximab Era Definitive clarification of the role of Rx only by a randomized trial UNFOLDER - Trial R * randomization upfront
36 17th Congress of EHA Amsterdam, the Nederlands, June 2012 R-CHOP21 vs R-CHOP14 IN 712 DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS OF A MULTICENTRIC RETROSPECTIVE STUDY FROM ITALIAN LYMPHOMA FOUNDATION (FIL) Luigi Rigacci Department of Hematology Azienda Ospedaliero Universitaria Careggi Florence EHA 2012 abs 1115 oral session
37 Patient characteristics Retrospective study from Jan 2002 to Dec consecutive DLBCL 7 Italian Hematological Centers R-CHOP21 vs R-CHOP14 R-CHOP21: 478 R-CHOP14: 234 p Median follow-up (months) Age > 60 years Median age < < Systemic Symptoms Stage I-II Stage III-IV Bulky disease Abnormal LDH IPI IPI IPI IPI Bone marrow Lymph nodes >= < Rigacci et al EHA 2012 abs 1115 oral session
38 Recruitment by age R-CHOP21 vs R-CHOP r-chop21 r-chop >79 Rigacci et al EHA 2012 abs 1115 oral session
39 R-CHOP21 vs R-CHOP14 Overall response rate and relapse R-CHOP21 (478) R-CHOP14 (234) p Tot (712) CR/CRu 367 (77%) 187 (80%) 554 (78%) PR 97 (20%) 40 (17%) 137 (19%) NR/PD 14 (3%) 7 (3%) n.s. 21 (3%) Relapse 47/367 (13%) 25/187 (13%) n.s. 72/554 (13%) Rigacci et al EHA 2012 abs 1115 oral session
40 Survival R-CHOP21 vs R-CHOP14 Rigacci et al EHA 2012 abs 1115 oral session
41 R-CHOP21 vs R-CHOP14 Toxicity during treatment Grade >=3 Hematol toxicity R-CHOP21 R-CHOP14 Neutropenia 31.7% 17% Anemia 2.5% 10.2% Thrombocytopenia 2% 0.8% Grade >=3 non-hematol toxicity Infection 3.9% 9.4% Hepatic 0.8% 0.8% Cardiac 0.2% 0.8% Neurological 6.2% 11.1% Rigacci et al EHA 2012 abs 1115 oral session
42 CRIZOTINIB OBTAINS DURABLE RESPONSES IN ADVANCED CHEMORESISTANT ALK+ LYMPHOMA PATIENTS A.Stasia (1), L.Guerra (2), L.Bernard (3), A.Cohen (4), M.King (5), R.Ordemann (6), M.Steurer (7), F.Farina (1), L.Dal Prà (1), M. Ceccon (8), L.Verga (2), E.M.Pogliani (1), R. Piazza (8), C.Gambacorti Passerini (1) 1 University of Milano Bicocca and S. Gerardo, Monza, Italy; 2 S. Gerardo Hospital, Monza, Italy; 3 Maisonneuve-Rosemont Hospital, Montreal, Canada; 4 Trillium Healt Centre, Toronto, Canada; 5 University of Tel-Aviv, Tel-aviv, Israel; 6 University of Dresden, Dresden, Germany; 7 University of Innsbruck, Innsbruck, Austria; 8 University of Milano Bicocca, Monza, Italy University of Milano Bicocca, Monza, Italy EHA 2012 abs 1153 oral session
43 ALK+ LYMPHOMAS: background ALK: 43% of Anaplastic Large Cell Lymphomas (ALCL) and 7 % non ALCL cases are NPM-ALK+ (Drexler H. et al. Leukemia 2001) ALCL ALK+ are responsive to cytotoxic drugs BUT relapses occur and bear a poor prognosis, given the intrinsic aggressiveness of this disease. University of Milano Bicocca, Monza, Italy N K El-Mallawany et al Nature 2012
44 Crizotinib: background is an ATP-competitive molecule inhibitor of c-met/hgfr rec tyrosine kinases with cellular IC50 values between 24 and 60 nm in NPM-ALK+ cells recommended dose in ALK+ lung adenocarcinoma is 250 mg BID; no study has been performed in ALK+ lymphomas. Crizotinib University of Milano Bicocca, Monza, Italy The structure of ALK in complex with Crizotinib
45 PTs UPN AGE N LINES of PRIOR CT Crizotinib: results Alk break BM % LDH, time to normalization FEVER time to normalization RESPONSE 01/SM 27 3 Y 3 > 0 29 days 2 days CR, /KK ABMT Y 8 > 0 22 days 10 days CR, 5 GG ABMT Y 65 > 0 35 days na PR, 2 SL 23 3 Y 0 na 3 days CR, +18 ZD 40 5 Y na 30 days na PR, 1 PR ABMT Y 15 -> 0 na 10 days CR, 2 JS 56 3 Y 0 30 days na CR, +13 RF 28 3 Y 0 na na PRO SI allobmt Y 0 na na CR, +8 ORR 89 % (95% C.I.: 60-99%) Durable (> 6 months) responses: 44% (95% C.I.: 19-73%) University of Milano Bicocca, Monza, Italy Stasia et al EHA 2012 abs 1153
46 Crizotinib: results Day 0 Day + 16 KK University of Milano Bicocca, Monza, Italy Stasia et al EHA 2012 abs 1153
47 Crizotinib: results Day 0 Day + 28 University of Milano Bicocca, Monza, Italy SL Spleen
48 Toxicity Ocular flashes grade 1-2 9/9 Peripheral Edema grade 1-2 1/9 Neutropenia grade 3 1/9 LFT elevation grade 2 1/9 University of Milano Bicocca, Monza, Italy 48
49 Crizotinib : conclusions Well tolerated over a long period of time (up to 2 years) Exerted a potent antitumor activity: ORR 89 % (95% C.I.: 60-99%) Durable (> 6 months) responses in 4/9 patients (44%, 95% C.I.: 19-73%) Crizotinib is being evaluated in a phase I B open label study (81013) in relapsed ALK+ lymphomas. Crizotinib in combination with other agents for first line treatment is under discussion. University of Milano Bicocca, Monza, Italy Stasia et al EHA 2012 abs 1153
50 Final queslons BEACOPP esc x 6 and PET guided IFRT should be considered the standard therapy of advanced HD? When Brentuximab Vedotin in advanced HD? R-CHOP 21 should be considered the standard therapy in all subgroups of DLBCL? Does local radiotherapy in DLBCL provide some benefit or add only toxicity?
51
52 Back up
53 Statistical analysis: multivariate R-CHOP21 vs R-CHOP14 Hazard Ratio R-CHOP21 1 R-CHOP (C.I. 95% ) Age > (C.I. 95% ) IPI (C.I. 95% ) IPI (C.I. 95% ) IPI (C.I. 95% ) Bulky 1.43 (C.I. 95% ) Rigacci et al EHA 2012 abs 1115
54 100 Overall survival Percent survival Time (months) University of Milano Bicocca, Monza, Italy
Radiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy
ABVD or BEACOPP for advanced Hodgkin lymphoma Not to BEACOPP Massimo Federico University of Modena and Reggio Emilia Italy What is the best Induction Therapy for Advanced Hodgkin Lymphoma? How to treat
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationChristian Rübe, and Michael Pfreundschuh, J Clin Oncol 32: by American Society of Clinical Oncology INTRODUCTION
VOLUME 32 NUMBER 11 APRIL 1 14 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma Gerhard Held, Niels Murawski,
More informationHodgkin Lymphoma Status of the art of treatment
11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationHodgkin Lymphoma Review of characteristics and treatment of elderly patients
Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationHodgkin. The PET World. Sally Barrington
Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationORIGINAL ARTICLE. Annals of Oncology 28: , 2017 doi: /annonc/mdx128 Published online 7 April 2017
Annals of Oncology 28: 54 546, 27 doi:.93/annonc/mdx28 Published online 7 April 27 ORIGINAL ARTICLE Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationTreatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research
Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following
More informationPost-ESMO Berne
Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationHodgkin Lymphoma in Older Patients
Hodgkin Lymphoma in Older Patients Andrew M. Evens, DO, MSc March 26 th, 2015 Professor of Medicine Chief, Division of Hematology/Oncology Director, Tufts Cancer Center Tufts Medical Center Elderly Hodgkin
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationORIGINAL ARTICLE CHARACTERISTICS AND OUTCOMES OF ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS-A SINGLE CENTRE EXPERIENCE
ORIGINAL ARTICLE CHARACTERISTICS AND OUTCOMES OF ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS-A SINGLE CENTRE EXPERIENCE Sohail Athar, Neelam Siddiqui, Abdul Hameed Department of Medical Oncology, Shaukat Khanum
More informationBendamustine: A Transversal * Chemotherapy Agent
Bendamustine: A Transversal * Chemotherapy Agent Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C., USA *Def Cutting across two lines, intersecting
More informationPeripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation
Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011
More informationThe role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas
Regular Article From www.bloodjournal.org by guest on April 30, 2018. For personal use only. CLINICAL TRIALS AND OBSERVATIONS The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic
More informationPET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be
PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationIs there a Role for Upfront Stem Cell Transplantation in Peripheral T-Cell Lymphoma: YES!
Is there a Role for Upfront Stem ell Transplantation in Peripheral T-ell Lymphoma: YES! Norbert Schmitz Dep. Hematology, Oncology and Stem ell Transplantation AK St. Georg Hamburg, Germany OS in the common
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationAddition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Original Article Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Bo Jia 1, Yuankai Shi 1, Suyi Kang 1, Sheng
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationASTRO Refresher Course Lymphoma. Chris Kelsey, M.D. Duke University Medical Center
ASTRO Refresher Course 2015 Lymphoma Chris Kelsey, M.D. Duke University Medical Center Disclosure Varian Medical Systems Research funding for lung cancer trial Learning Objectives Awareness of Deauville
More informationInterim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal
Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline
More informationAngioimmunoblastic T-cell lymphoma: nobody knows what to do...
Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte
More informationUpdates in T cell Lymphoma
Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationOn behalf of the Israel Cooperative Lymphoma Group. A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A.
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan for patients with advanced highrisk Hodgkin s lymphoma A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler,
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationDoes the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
Annals of Hematology (2018) 97:2129 2135 https://doi.org/10.1007/s00277-018-3437-z ORIGINAL ARTICLE Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
More informationMANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
More informationNon-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection. Arnold Freedman, M.D.
2017 Master Class for Oncologists Non-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection Arnold Freedman, M.D. 2018 Master Class Course Disclosure Disclosure
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationDr. Andrea Gallamini - Hematology Department Azienda Ospedaliera S. Croce e Carle Cuneo Italy
High-dose sequential chemotherapy (HDS) followed by autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin s lymphoma. Long term results. Dr. Andrea Gallamini - Hematology Department
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationFirenze, settembre 2017 Novità dall EHA LINFOMI Umberto Vitolo
Firenze, 22-23 settembre 2017 Novità dall EHA LINFOMI Umberto Vitolo Hematology University Hospital Città della Salute e della Scienza Torino, Italy Disclosures Umberto Vitolo Research Support/P.I. Employee
More informationAddition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
VOLUME 46 ㆍ NUMBER 2 ㆍ June 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationA CME-certified Oncology Exchange Program
A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett
More informationLYMPHOMA IN OLDER PEOPLE. Ama Rohatiner, St. Bartholomew s Hospital, Londonj
LYMPHOMA IN OLDER PEOPLE Ama Rohatiner, St. Bartholomew s Hospital, Londonj LYMPHOMA IN OLDER PEOPLE PERSPECTIVES HALF OF ALL NEWLY-DIAGNOSED PTS. WITH LYMPHOMA ARE >60 MAY REQUIRE DIFFERENT MANAGEMENT
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationPatient Case Studies & Panel Discussion
Patient Case Studies & Panel Discussion Panelists: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center; Ranjana H. Advani, MD, Stanford Cancer Institute; Andrew D. Zelenetz, MD, PhD, Memorial
More informationPeripheral T-cell lymphomas (PTCL) Specified and Unspecified. Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles
Peripheral T-cell lymphomas (PTCL) Specified and Unspecified Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles BHS seminar 12, 07 March 2015 Peripheral T-cell lymphomas (PTCL) Specified and
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationOriginal Article. Introduction
Original Article Radiat Oncol J 217;35(4):317-324 https://doi.org/1.3857/roj.217.451 pissn 2234-19 eissn 2234-3156 Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck
More informationCME Information. Y-ibritumomab tiuxetan to that of rituximab maintenance for patients with newly diagnosed follicular lymphoma (FL).
CME Information LEARNING OBJECTIVES Compare the efficacy of consolidation therapy with a single dose of 90 Y-ibritumomab tiuxetan to that of rituximab maintenance for patients with newly diagnosed follicular
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationOutcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions
Outcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions AA Moccia, S Gobba, A Conconi, S Diem, L Cascione, K Aprile von Hohenstaufen, W Gulden Sala, A Stathis, F Hitz, G Pinotti,
More informationElderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia
Elderly Patients with Hodgkin s Lymphoma: FIL experience Massimo Federico University of Modena and Reggio Emilia RESULTS OF VbMp CHEMOTHERAPY REGIMEN IN ELDERLY PATIENTS WITH HODGKIN DISEASE: THE GISL
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationShould peripheral T-cell lymphoma be treated by autologous or allogeneic SCT?
Francesco d Amore, MD, PhD Dept. Of Hematology Aarhus University Hospital, Aarhus, Denmark Should peripheral T-cell lymphoma be treated by autologous or allogeneic SCT? Disclosure of Interest: Nothing
More informationBrentuximab vedotin in Relapsed Primary Mediastinal Large B-Cell Lymphoma: Results from a Phase 2 Clinical Trial
Blood First Edition Paper, prepublished online March 6, 2017; DOI 10.1182/blood-2017-01-764258 Letter To Blood Brentuximab vedotin in Relapsed Primary Mediastinal Large B-Cell Lymphoma: Results from a
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More information